| scholarly article | Q13442814 |
| P50 | author | Andreas Schneeweiss | Q37074948 |
| Michael P. Lux | Q37372079 | ||
| Sara Brucker | Q63345510 | ||
| Peter A. Fasching | Q64005064 | ||
| P2093 | author name string | Michael P Lux | |
| Peter A Fasching | |||
| Volkmar Müller | |||
| Johannes Ettl | |||
| Achim Wöckel | |||
| Markus Wallwiener | |||
| Jens Huober | |||
| Andreas Schneeweiss | |||
| Hans Tesch | |||
| Wolfgang Janni | |||
| Diana Lüftner | |||
| Andreas D Hartkopf | |||
| Tanja N Fehm | |||
| Florin-Andrei Taran | |||
| Florian Schütz | |||
| Erik Belleville | |||
| Friedrich Overkamp | |||
| Hans-Christian Kolberg | |||
| Constanza Pontones | |||
| Adriana Titzmann | |||
| P2860 | cites work | Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial | Q37604182 |
| Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial | Q37709879 | ||
| Genome-wide association studies in common cancers--what have we learnt? | Q37736894 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial | Q38373098 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Random | Q39500625 | ||
| Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy | Q40178893 | ||
| Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods | Q41011976 | ||
| Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients | Q43927056 | ||
| Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer | Q44903975 | ||
| Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). | Q45352687 | ||
| Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Q46103372 | ||
| Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial | Q46165703 | ||
| HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics | Q46188099 | ||
| Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer | Q46217329 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer | Q47212593 | ||
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials | Q47308042 | ||
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy | Q47322152 | ||
| Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study | Q47552886 | ||
| Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. | Q48566091 | ||
| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 | ||
| Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Q26751253 | ||
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
| Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | Q29417100 | ||
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 | ||
| Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08). | Q33862578 | ||
| Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment | Q34074094 | ||
| Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. | Q34155828 | ||
| Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer | Q34371159 | ||
| 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer | Q34538363 | ||
| I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. | Q34687264 | ||
| Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy | Q34743488 | ||
| Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial | Q34919537 | ||
| Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer | Q34996647 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer | Q35171086 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| 19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
| Common breast cancer susceptibility loci are associated with triple-negative breast cancer | Q35891162 | ||
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
| A review of 146 cases of carcinoma of the breast operated on between 1930 and 1943 | Q36037358 | ||
| The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
| Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. | Q36251476 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk | Q36600605 | ||
| Genome-wide association analysis identifies three new breast cancer susceptibility loci | Q36842233 | ||
| Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. | Q36901398 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study | Q56352005 | ||
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | Q57107580 | ||
| Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis | Q57110036 | ||
| Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer | Q57808778 | ||
| BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients | Q57990746 | ||
| Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea | Q58124814 | ||
| Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | Q58797082 | ||
| Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Adva | Q60050114 | ||
| Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | Q60683126 | ||
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 | ||
| Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | Q62583133 | ||
| TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes | Q62583463 | ||
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials | Q64069775 | ||
| Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer | Q78410812 | ||
| Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients | Q84949060 | ||
| Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: An evaluation of 8323 patients | Q88484370 | ||
| Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer | Q88971883 | ||
| The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer | Q89305074 | ||
| Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial | Q91341844 | ||
| West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer | Q91747473 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P304 | page(s) | 470-482 | |
| P577 | publication date | 2019-05-21 | |
| P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
| P1476 | title | Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel | |
| P478 | volume | 79 |
| Q92886173 | Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019) |
| Q99241101 | Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres |
| Q92244163 | Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer |
| Q90092211 | Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies |
Search more.